Clinical Trials Logo

ALK-POSITIVE NSCLC clinical trials

View clinical trials related to ALK-POSITIVE NSCLC.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04056572 Recruiting - ALK-positive NSCLC Clinical Trials

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Start date: August 13, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of TQ-B3139 in subjects with ALK-positive non-small cell lung cancer that have demonstrated progression during or after crizotinib treatment whether or not previously treated with cytotoxic chemotherapy.

NCT ID: NCT04009317 Recruiting - ALK-positive NSCLC Clinical Trials

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Start date: August 13, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK inhibitor.

NCT ID: NCT03804541 Recruiting - ALK-POSITIVE NSCLC Clinical Trials

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

Start date: December 28, 2018
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] Ensartinib in healthy Chinese male subjects. The study will be conducted into two steps:Firstly, 2 subjects are enrolled in to participate in the pilot study to grope for the completion date of plasma, urine and feces sampling on the 3rd day post-dose and onwards. Then, the collection time of blood and excreta samples (urine and feces) from the subsequent 4-6 subjects will be adjusted according to the pilot study.